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Synthetic Chemistry
Automated, Accelerated Nanoscale Synthesis of Iminopyrrolidines
Angelina Osipyan+, Shabnam Shaabani+, Robert Warmerdam, Svitlana V. Shishkina,
Harry Boltz, and Alexander Dçmling*
In memory of Rolf Huisgen
Abstract: Miniaturization and acceleration of synthetic
chemistry is an emerging area in pharmaceutical, agrochem-
ical, and materials research and development. Herein, we
describe the synthesis of iminopyrrolidine-2-carboxylic acid
derivatives using chiral glutamine, oxo components, and
isocyanide building blocks in an unprecedented Ugi-3-compo-
nent reaction. We used I-DOT, a positive-pressure-based low-
volume and non-contact dispensing technology to prepare
more than 1000 different derivatives in a fully automated
fashion. In general, the reaction is stereoselective, proceeds in
good yields, and tolerates a wide variety of functional groups.
We exemplify a pipeline of fast and efficient nanomole-scale
scouting to millimole-scale synthesis for the discovery of
a useful novel reaction with great scope.
Synthesis and exploration of chemical space is usually
a sequential, expensive, and slow process. However, accel-
eration and miniaturization of synthetic chemistry is becom-
ing more and more important for the timely discovery of
novel drugs and materials in an age of big data and artificial
intelligence.[1] For example, nanoscale optimization proce-
dures to explore the scope and limitations of Pd-catalyzed
cross-coupling reactions were recently described.[2] Miniatur-
ization of organic chemistry to a nanoscale is not only time-
and cost-effective but also dramatically reduces reagent and
solvent consumption and, thus, the ecological footprint of
chemistry.[3]
As part of our ongoing interest in proteolysis targeting
chimeras (PROTACs), we aimed to produce libraries cen-
tered around the glutarimide pharmacophore addressing the
E3 ligase Cereblon using multicomponent reactions (MCR).[4]
For this, we went back to a report of the use of glutamine
(Gln) in the Ugi reaction (U-5C-4CR), yielding highly
substituted glutarimide derivatives (Figure 1A).[5] Surpris-
ingly, the repetition of the reaction in our hands resulted in
the formation of hitherto unprecedented iminopyrrolidine-2-
carboxylic acid derivatives (P), as proven by an X-ray
structure analysis (Figure 1A,C).
Opportunistically, we figured that the iminopyrrolidine
moiety shares key pharmacophoric and structural features of
a number of biologically relevant compounds (Figure 1B).[6]
For example ()-linarinic acid has anti-ischemia-properties,
ectoine is an osmoprotectant that helps organisms survive
extreme osmotic stress,[7] and 5-amino-3,4-dihydro-2H-pyr-
role-2-carboxylate (ADPC) is an artificially engineered
osmoprotectant.[8] Traditional methods for the synthesis of
ADPC start from the commercial pyroglutamatic or glutamic
acid exhibiting a long target synthesis time, harsh reaction
conditions, difficult-to-obtain and expensive starting materi-
als and reagents, and limited diversity of substituents.[9] Thus,
novel synthetic routes towards the iminopyrrolidine moiety
are in high demand. We felt that our newly discovered Ugi-
pathway towards the iminopyrrolidine scaffold shows unique
advantages and is, therefore, worthwhile to further exploit.
Initially, we applied various reaction conditions in order to
find the most suitable protocol to obtain the target molecules
(Supporting Information, Table S1). For this purpose, we used
l-glutamine, cyclohexanone A12, and benzyl isocyanide B23
in the Ugi reaction to yield I-D18. An extensive survey of
solvent, concentration, and time revealed the optimized
reaction conditions of the “green” solvent mixture of
ethanol/water 1:1 at room temperature for 16 h at a reactant
concentration of 0.5m (Scheme 1). The desired product I-D18
was formed in 83 % isolated yield under mild room temper-
ature conditions.
Missing structural complexity and broad functional-group
compatibility are well-described issues of many synthetic
methods, which has also been named the “dark space of
chemical reactions”.[2b] Therefore a platform that can enable
systematic reaction evaluation and data capture to survey the
dark space of chemical reactions and help to define practical
limitations of chemical reactions is of great use. Following our
encouraging initial results, we tested the generality of the one-
pot cyclization protocol on a diverse set of 44 oxo components
and 44 different isocyanides using automated nanoscale
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synthesis (Figure 2), not taking into account stereochemistry,
theoretically 1936 combinations. The building block complex-
ity ranged from simple aliphatic (A1, A5) to polycyclic (B10),
3- to 6-membered ring size (A13, A3, A42, B24), from
aromatic to heterocyclic, including indole (A41, B26), tetra-
hydropyran (A9), tetrahydrofuran (B14), furan (A30), mor-
pholine (B5, B22), piperazine (A17), thiophene (A24).
Multiple functional groups were tested for reaction compat-
ibility, including hydroxyl (A2), ether (B42), thioether (A7),
amine (B5, B22), ester (B1, B31, B37), carbamate (B9, B11),
acetal (B12), nitrile (A14, B43), ene (A15, A19, A29), azide
(B32), and halogens (A34, A36, A37, A44, B15).
The synthesis was performed with a nano dispensing
instrument based on the Immediate drop-on-demand tech-
nology (I-DOT), a non-contact, pressure-based dispensing
technology (Figure 2A).[10] Applying a well-defined pressure
pulse on top of a microliter plate with holes in the bottom of
each well forms a highly precise nanoliter droplet that is
released into any target plate. We used 384-well polypropy-
lene destination plates for our syntheses. Each destination
plate was charged with a total of 660 nL of reagents with
a final concentration of 0.125 M. Three 384-well plates were
filled using an algorithm developed in-house that allows for
random combinations of building block dispersions thus
removing any synthesis bias (Supporting Information, Page
S5). The total length of the dispensing procedure was 15 min
per 384 well-plate.
Next, the analysis of the plates was performed using direct
mass spectrometry (MS) (Figure 3 and Supporting Informa-
tion, Pages S91 and S92). As described recently, the reaction
mixtures were injected directly into the mass spectrometer
after 16 h reaction time.[11] The reaction success was automati-
cally categorized using our software developed in-house
according to three different classes (Supporting Information,
Page S43). Reactions showing a major MS peak for the M +
H, M + Na, M + K, showing the corresponding peaks but not
as highest peaks or not showing the compounds peaks at all
were classified as green, yellow, and blue, respectively
(Figure 3 and Supporting Information, Figure S3).
12 compounds from a 384-well plate were randomly
selected for resynthesis on a mmol scale to determine yields,
for thorough analytical characterization and further investiga-
tion of the stereochemistry of the reaction (Figure 3 and
Supporting Information, Figure S6). Cyclic ketones gave good
yields (I-D18, 83%, and I-E13, 82%), less so cyclobutanone (I-
H18, 34%). Furthermore, aldehydes gave poor yields at room
Scheme 1. Optimized condition for the U-5C-3CR.
Figure 1. Evolution of iminopyrrolidines. A) The Ugi-type reaction of l-Gln with oxo components and isocyanides yields iminopyrrolidines (P) and
not glutarimides. B) Biologically active compounds based on the iminopyrrolidine pharmacophore. C) Crystal structure of compound I-D18,
proving the structural outcome of the U-3CR.[20]
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temperature, while a slight increase of temperature to 408C
enhanced the yields (I-C11, I-D20, I-E21, I-F16, I-I23, I-M20, I-
O2). In comparison with aromatic aldehydes (I-C11, I-D20),
aliphatic aldehydes gave higher yields (I-I23, I-M20, I-O2).
Paraformaldehyde, in combination with aromatic isocyanide,
resulted in I-F16 in only 37% yield. Benzyl isocyanides with
electron-donating groups, as well as all aliphatic isocyanides,
were applied in this reaction to give the corresponding
products with good to moderate yields. Amino acid isocyanide
furnished product in good yields (I-E13, 82%).
When chiral substrates are used in the Ugi reaction, such
as a-amino acids, there is uncertainty about stereo retention
and racemization during the reaction.[7a,12] Thus, a critical
question is whether the stereochemical integrity of the chiral
glutamine center is maintained during the reaction and
whether the formation of the 5-membered ring takes place
without racemization. Therefore, the synthesis of I-D18 using
enantiopure d-Gln and l-Gln, and racemic d/l-Gln was
carried out under the same reaction conditions. The corre-
sponding products obtained were subjected to chiral SFC-MS
analysis (SFC = supercritical fluid chromatography, Support-
ing Information, Figure S7). The results indicated that the
reaction is working with stereo retention in the Gln stereo-
center. In the case of prochiral oxo-component usage,
diastereomers are formed (Figure 3).
A plausible reaction mechanism is shown in Scheme 2.
Firstly, glutamine reacts with the oxo-component to form the
imine. Protonation by the carboxylic-acid group activates the
imine, forming the iminium ion (A) and prepares for the
nucleophilic addition of the isocyanide to give the nitrilium
ion (B). The nucleophilic trapping of this intermediate (B) by
the carboxylic acid counter anion affords the cyclic imidoyl
species (C). This intermediate undergoes a “vicarious Mumm-
rearrangement” due to the impossibility of the Mumm-
rearrangement to occur (which would lead to highly strained
a-lactams). Then, the intermediate (D) forms, which under-
goes the intramolecular nucleophilic attack of the amide
carbon by the secondary amine to give the final product (P).
The products are charged zwitterions and in the solid-state
form an intramolecular hydrogen bond between the carboxyl
Figure 2. Diversity-oriented nanoscale synthesis of iminopyrrolidines. A) Reaction condition for nanoscale synthesis. B) Oxo component building
blocks. C) Isocyanide building blocks.
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group and the exocyclic imine featuring an 8-membered ring
(Supporting Information, Figure S8).
The toolbox of transformations used in modern drug discovery
is heavily biased toward fewer than ten transformations.[13] The
overuse of these most popular reactions in medicinal chemistry
leads to a limited, crowded, and narrow chemistry space.[14]
Commercial availability of reagents, high robustness of the
reactions, and pressure on delivery were proposed as reasons for
the overuse of a handful of reactions, while many new synthetic
methodologies are neglected.[13a] How-
ever, new synthetic methodologies result
in making and exploring structures that
were previously inaccessible.[15] Amongst
those are multicomponent reactions that
have the benefit of simple one-pot proce-
dures, almost unlimited scaffold diversity,
and great functional group compatibil-
ity.[16] Herein, we describe such a novel
transformation leading to unprecedented
iminopyrrolidines in a one-pot MCR
procedure. The products are non-planar
zwitterionic amino acids formed by the
stereo-selective and -preserving reaction
of chiral glutamine with oxo components
and isocyanides according to a complex
Ugi reaction mechanism. We used auto-
mated I-DOT nano dispensing to perform
a “real world” evaluation of the new reaction in more than 1000
examples. The benefit of the nanoscale synthesis is a rapid
automated evaluation of the reaction, synthesis of a large chemical
space while saving lots of chemicals and potentially environ-
mentally hazardous solvent, thus considerably reducing the
ecological footprint of the chemistry. The total chemical consump-
tion in precious reagents and solvent was less than 0.6 mg for the
1152 reactions performed on a nanoscale, which compares very
favorable to approximately 400 g of reagents and 12 L of solvents
Figure 3. A 384-well synthesis plate, direct MS-based quality control, and resynthesized compounds on a mmol scale with isolated yields. I-E21
and I-H18 are shown blue because of I-DOT reagent transfer failure, however their synthesis showed medium product formation.
Scheme 2. Proposed reaction mechanism.
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when the same number of reactions is done on a mmol scale. The
automation aspect of our work synergizes and is of equal
importance to synthesize a large chemical space that is clearly
beyond human capabilities.[17] Moreover, it reduces errors,
increases speed and safety, leads to better reproducibility, and
more efficient and cheaper workflow.[18] Finally, the big data
generated can be potentially leveraged by machine-learning
software.[19] Altogether the results of our miniaturized, automated,
and accelerated platform established a useful new reaction towards
drug-like compounds with great functional group compatibility.
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